Company intelligence / Profile preview
Minovia Therapeutics
Haifa, Israelminoviatx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
FDA clearance for Phase 2 clinical trial of MNV-201 in Pearson Syndrome (April 2025). Preliminary clinical data for MNV-201 in low-risk Myelodysplastic Syndrome demonstrates safety and efficacy. Five patients with single-large scale mtDNA deletion syndromes have been successfully dosed.
- Therapeutic areas
- HematologyRare DiseasesMetabolic Disorders
- Modalities
- Mitochondrial cell therapyHematopoietic stem cell therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Astellas Pharma Inc.BioSpherix
Beyond the preview
Go deeper on Minovia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Minovia Therapeutics.